Andy Whiting, Nevrargenics
"Look at oncology 50 years ago. With huge amounts of investment we now think that most form of cancer are treatable. With investment, understanding, time and research that's possible in neurodegeneration - that you can not just slow or even stop but reverse and repair it." Andy Whiting is the CEO of Nevrargenics, a Biotech company spun out of his research at Durham University using dual-acting retinoic acid receptor modulators as a novel treatment for neurodegenerative diseases. Andy talked to us about his decision to leave academia to run the company, how he knew when the research had the potential to become a real drug, and why uncertainty and risk shouldn't hold your career back. Enjoy!